Saccharomyces boulardii and Secretory IgA Enhancement

Clinical Recommendations

• The American Gastroenterological Association conditionally recommends S. boulardii for prevention of C. difficile infection in patients receiving antibiotics, showing a 59% reduction in C. difficile-associated diarrhea recurrence 1, 2
• The effective dosing in clinical studies is typically 1g or 3×10¹⁰ CFU/day, and should be started at the beginning of any intervention and continued throughout the treatment course 3

Contraindications and Precautions

• S. boulardii is absolutely contraindicated in immunocompromised individuals due to risk of fungemia 3, 4

Quality of Evidence

• The overall quality of evidence supporting S. boulardii's specific effects on intestinal immune function, including sIgA modulation, is rated as low to moderate 3